What are the adverse reactions of Idecabtagene vicleucel?

Idecabtagene vicleucel is an innovative immunotherapy approach specifically targeted at adult patients with relapsed or refractory multiple myeloma (MM). It genetically modifies autologous T cells so that they can recognize and attack cancer cells expressing B cell maturation antigen (BCMA). This therapy is generally indicated for patients who have failed to achieve effective response after two or more prior therapies (eg, immunomodulators, proteasome inhibitors, and anti-CD38 monoclonal antibodies).

In clinical studies, the application of Akivelense has shown significant therapeutic effects, but it has also been accompanied by a series of side effects. The most common side effects include neutropenia, anemia, and thrombocytopenia. These are due to treatment-induced reductions in blood cells, which may lead to an increased risk of infection, fatigue, and bleeding tendencies.

In addition, cytokine release syndrome (CRS) is an important side effect that usually manifests as fever, fatigue, nausea and other symptoms, and may even develop into more serious complications such as pneumonia. Other common side effects include hypophosphatemia, diarrhea, leukopenia, hypokalemia, lymphopenia, viral infection, headache, hypocalcemia, and hypomagnesemia. Patients may experience varying degrees of discomfort after treatment, such as joint pain and a persistent feeling of fatigue. It is important to note that CRS is a serious side effect that needs to be closely monitored during the treatment of Akivelense. Once corresponding symptoms appear, timely intervention is crucial.

Alkavilenza is not suitable for patients who cannot clear existing white blood cells with chemotherapy and therefore require adequate evaluation before treatment. The frequency and severity of these side effects may vary depending on individual patients. Clinicians need to develop personalized treatment plans based on the patient's specific conditions and provide corresponding supportive treatment to reduce the impact of side effects.

Reference materials:https://www.drugs.com/history/abecma.html